A process for preparing an organo-iodinated compound, comprising the following steps: a) acylating 2,4,6-triiodo-5-aminoisophthalic acid of formula (A) below: ##STR00001## to obtain an intermediate compound Ya; b) chlorinating the intermediate compound Ya to obtain an organo-iodinated intermediate compound Yb; c) amidating the organo-iodinated intermediate compound Yb to obtain an intermediate compound Yc; and d) deprotecting the intermediate compound Yc, the steps a), b), c) and d) being carried out without isolation of at least one intermediate compound chosen from Ya and Yc.

Provided are a novel pseudoceramide compound and uses thereof. The pseudoceramide has antioxidant, anti-inflammatory, skin whitening, and moisturizing effects. In addition, the pseudoceramide can be synthesized in a simple and economically advantageous manner and is free from problems associated with the preparation of cosmetic formulations resulting from low hydrophilicity, thus being suitable for use in cosmetic applications.

Provided are a novel pseudoceramide compound and uses thereof. The pseudoceramide has antioxidant, anti-inflammatory, skin whitening, and moisturizing effects. In addition, the pseudoceramide can be synthesized in a simple and economically advantageous manner and is free from problems associated with the preparation of cosmetic formulations resulting from low hydrophilicity, thus being suitable for use in cosmetic applications.

Provided are a novel pseudoceramide compound and uses thereof. The pseudoceramide has antioxidant, anti-inflammatory, skin whitening, and moisturizing effects. In addition, the pseudoceramide can be synthesized in a simple and economically advantageous manner and is free from problems associated with the preparation of cosmetic formulations resulting from low hydrophilicity, thus being suitable for use in cosmetic applications.

The present invention relates generally to: the cosmetic or pharmaceutical use of avenanthramide L or an oat extract comprising avenanthramide L; avenanthramide L or an oat extract comprising avenanthramide L as a neurokinin-1 receptor NK1R antagonist; and a method for preparing of preparing avenalumic acid and/or avenanthramide L.

The present invention relates generally to: the cosmetic or pharmaceutical use of avenanthramide L or an oat extract comprising avenanthramide L; avenanthramide L or an oat extract comprising avenanthramide L as a neurokinin-1 receptor NK1R antagonist; and a method for preparing of preparing avenalumic acid and/or avenanthramide L.

The present invention relates to new methods of manufacturing benzoquinoline inhibitors of vesicular monoamine transporter 2 (VMAT2), and intermediates thereof.

##STR00001##

The present invention relates to new methods of manufacturing benzoquinoline inhibitors of vesicular monoamine transporter 2 (VMAT2), and intermediates thereof.

##STR00001##

The present invention relates to new methods of manufacturing benzoquinoline inhibitors of vesicular monoamine transporter 2 (VMAT2), and intermediates thereof.

##STR00001##

Disclosed are methods for preparing compound S-1 (S-1) from (R)-2-bromobutanoic acid prepared by treating (R)-2-aminobutanoic acid with an alkali metal nitrite compound and hydrobromic acid.

##STR00001##